Financials LifeTech Scientific Corporation

Equities

Delayed Hong Kong S.E. Other stock markets 04:26:35 03/07/2024 BST			5-day change	1st Jan Change
1.46 ^HKD	+2.82%		+0.69%	-38.30%

05-16	LifeTech Scientific Completes Follow-up of Phase 2 Clinical Study of IBS Coronary Scaffold	MT
05-15	LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	5,752	17,330	13,808	10,550	9,890	6,119	-
Enterprise Value (EV) ¹	5,734	16,373	13,808	10,550	9,890	6,119	6,119
P/E ratio	43 x	76.4 x	46.6 x	30.8 x	36.2 x	18.9 x	14.7 x
Yield	-	-	-	-	-	-	-
Capitalization / Revenue	8.6 x	27 x	14.9 x	-	7.8 x	4.15 x	3.45 x
EV / Revenue	8.6 x	27 x	14.9 x	-	7.8 x	4.15 x	3.45 x
EV / EBITDA	38.3 x	53 x	-	-	39.8 x	13.1 x	11.1 x
EV / FCF	302,807,058 x	79,697,552 x	64,815,519 x	-	-	-	-
FCF Yield	0%	0%	0%	-	-	-	-
Price to Book	4.99 x	7.4 x	5.14 x	-	2.93 x	1.76 x	1.57 x
Nbr of stocks (in thousands)	4,320,033	4,626,998	4,630,030	4,630,030	4,630,232	4,630,512	-
Reference price ²	1.332	3.745	2.982	2.279	2.136	1.321	1.321
Announcement Date	30/03/20	30/03/21	30/03/22	29/03/23	28/03/24	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	668.9	642.3	925.3	-	1,267	1,474	1,774
EBITDA ¹	150	327.1	-	-	248.6	467	550
EBIT ¹	94.84	264.5	328.7	-	383.3	379	456
Operating Margin	14.18%	41.18%	35.53%	-	30.25%	25.71%	25.7%
Earnings before Tax (EBT) ¹	170.8	242.6	332.9	-	175.6	379	460
Net income ¹	129.2	216.1	292.5	325.3	263.2	328	399
Net margin	19.32%	33.64%	31.61%	-	20.77%	22.25%	22.49%
EPS ²	0.0310	0.0490	0.0640	0.0740	0.0590	0.0700	0.0900
Free Cash Flow	19	217.4	213	-	-	-	-
FCF margin	2.84%	33.85%	23.02%	-	-	-	-
FCF Conversion (EBITDA)	12.66%	66.47%	-	-	-	-	-
FCF Conversion (Net income)	14.7%	100.63%	72.84%	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	30/03/20	30/03/21	30/03/22	29/03/23	28/03/24	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-	-
Net Cash position	18.8	957	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	19	217	213	-	-	-	-
ROE (net income / shareholders' equity)	10.8%	12.4%	12.1%	-	8.4%	9.9%	10.8%
ROA (Net income/ Total Assets)	7.82%	9.14%	-	-	6.28%	7.9%	8.8%
Assets ¹	1,652	2,363	-	-	4,193	4,152	4,534
Book Value Per Share ²	0.2700	0.5100	0.5800	-	0.7300	0.7500	0.8400
Cash Flow per Share ²	-	-	-	-	0.0900	0.0700	0.0900
Capex ¹	114	105	276	-	206	153	103
Capex / Sales	17.05%	16.36%	29.81%	-	16.25%	10.38%	5.81%
Announcement Date	30/03/20	30/03/21	30/03/22	29/03/23	28/03/24	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.321 CNY

Average target price

2.436 CNY

Spread / Average Target

+84.35%

	1st Jan change	Capi.
LIFETECH SCIENTIFIC CORPORATION	-38.30%	824M
THERMO FISHER SCIENTIFIC	+0.59%	207B
DANAHER CORPORATION	+3.92%	181B
INTUITIVE SURGICAL, INC.	+30.07%	155B
BOSTON SCIENTIFIC CORPORATION	+32.42%	112B
SIEMENS HEALTHINEERS AG	+1.98%	64.42B
EDWARDS LIFESCIENCES CORPORATION	+19.65%	54.38B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.86%	47.43B
AGILENT TECHNOLOGIES, INC.	-9.53%	37.17B
GE HEALTHCARE TECHNOLOGIES INC.	-1.28%	34.81B